Login to Your Account

Pharma: Other News To Note

Wednesday, July 3, 2013

• Merck and Co. Inc., of Whitehouse Station, N.J., said the FDA approved new labeling for Isentress (raltegravir), including 240-week results from the STARTMRK study, a double-blind, Phase III noninferiority trial evaluating an integrase inhibitor for treatment-naive adults patients with HIV-1 infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription